1. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
- Author
-
An Z, Lei T, Duan L, Hu P, Gou Z, Zhang L, Durand-Gasselin L, Wang N, Wang Y, and Gu F
- Subjects
- Adenoma diagnostic imaging, Adenoma metabolism, Adenoma pathology, Adult, Antineoplastic Agents therapeutic use, Blood Glucose metabolism, China, Delayed-Action Preparations, Female, Glycated Hemoglobin metabolism, Growth Hormone-Secreting Pituitary Adenoma diagnostic imaging, Growth Hormone-Secreting Pituitary Adenoma metabolism, Growth Hormone-Secreting Pituitary Adenoma pathology, Human Growth Hormone metabolism, Humans, Injections, Intramuscular, Injections, Subcutaneous, Insulin-Like Growth Factor I metabolism, Magnetic Resonance Imaging, Male, Middle Aged, Peptides, Cyclic therapeutic use, Somatostatin administration & dosage, Somatostatin therapeutic use, Treatment Outcome, Tumor Burden, Adenoma drug therapy, Antineoplastic Agents administration & dosage, Growth Hormone-Secreting Pituitary Adenoma drug therapy, Peptides, Cyclic administration & dosage, Somatostatin analogs & derivatives
- Abstract
Background: Lanreotide autogel is a somatostatin analog (SSA) approved for the treatment of acromegaly in 73 countries worldwide; however, it is not yet approved in China. The aim of this study was to evaluate the efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release (PR) in Chinese patients with active acromegaly., Methods: LANTERN was a phase 3, randomized, open-label, non-inferiority study. Patients with active acromegaly who had undergone surgery ≥3 months prior, or were unlikely or unable to undergo surgery, were treated with lanreotide autogel 60/90/120 mg (monthly deep subcutaneous injection) or lanreotide 40 mg PR (intramuscular injection every 7, 10, or 14 days) for 32 weeks. Primary endpoint was mean change-from-baseline in age-adjusted insulin-like growth factor-1 (IGF-1) standard deviation scores (SDS) at the end-of-study. Secondary endpoints included: growth hormone (GH) levels ≤2.5 μg/L or ≤ 1.0 μg/L, ≥20% reduction in tumor volume (TV) and safety., Results: In total, 128 patients were randomized and received study treatment. Lanreotide autogel was non-inferior to lanreotide 40 mg PR: treatment difference (95% CI) for IGF-1 SDS between groups was - 0.32 (- 0.74, 0.11; per protocol population) and - 0.27 (- 0.63, 0.09; intention-to-treat [ITT] population), respectively. Reductions in IGF-1 (- 6.453 vs - 7.003) and GH levels (- 9.548 μg/L vs - 13.182 μg/L), and the proportion of patients with ≥1 acromegaly symptom (- 20.3% vs - 32.5%) were observed from baseline to end-of-study in lanreotide autogel and lanreotide 40 mg PR groups, respectively. In the lanreotide autogel group, 45.5% (25/55) patients achieved ≥20% reduction in TV compared with 50.9% (25/53) in lanreotide 40 mg PR group (ITT). Safety profiles were similar in both treatment groups., Conclusions: Lanreotide autogel was non-inferior to lanreotide 40 mg PR in Chinese patients with active acromegaly after 32 weeks of treatment., Trial Registration: Retrospectively registered on ClinicalTrials.gov: NCT02493517 (9 July 2015); prospectively registered on chinadrugtrials.org.cn: CTR20140698 (24 October 2014).
- Published
- 2020
- Full Text
- View/download PDF